174 related articles for article (PubMed ID: 22553196)
21. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Campone M; Beck JT; Gnant M; Neven P; Pritchard KI; Bachelot T; Provencher L; Rugo HS; Piccart M; Hortobagyi GN; Nunzi M; Heng DY; Baselga J; Komorowski A; Noguchi S; Horiguchi J; Bennett L; Ziemiecki R; Zhang J; Cahana A; Taran T; Sahmoud T; Burris HA
Curr Med Res Opin; 2013 Nov; 29(11):1463-73. PubMed ID: 23962028
[TBL] [Abstract][Full Text] [Related]
23. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
24. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
25. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Hortobagyi GN; Chen D; Piccart M; Rugo HS; Burris HA; Pritchard KI; Campone M; Noguchi S; Perez AT; Deleu I; Shtivelband M; Masuda N; Dakhil S; Anderson I; Robinson DM; He W; Garg A; McDonald ER; Bitter H; Huang A; Taran T; Bachelot T; Lebrun F; Lebwohl D; Baselga J
J Clin Oncol; 2016 Feb; 34(5):419-26. PubMed ID: 26503204
[TBL] [Abstract][Full Text] [Related]
26. Everolimus Plus Letrozole for Treatment of Patients With HR
Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Blackwell K; Burris H; Gomez P; Lynn Henry N; Isakoff S; Campana F; Gao L; Jiang J; Macé S; Tolaney SM
Breast Cancer Res Treat; 2015 Nov; 154(2):287-97. PubMed ID: 26497877
[TBL] [Abstract][Full Text] [Related]
28. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
30. The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer.
Gnant M
Curr Oncol Rep; 2013 Feb; 15(1):14-23. PubMed ID: 23054937
[TBL] [Abstract][Full Text] [Related]
31. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists.
Yardley DA
Clin Breast Cancer; 2014 Oct; 14(5):297-308. PubMed ID: 25065566
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
33. mTOR inhibitors in breast cancer: a systematic review.
Zagouri F; Sergentanis TN; Chrysikos D; Filipits M; Bartsch R
Gynecol Oncol; 2012 Dec; 127(3):662-72. PubMed ID: 22967800
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
[TBL] [Abstract][Full Text] [Related]
35. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
Hadji P; Coleman R; Gnant M
Crit Rev Oncol Hematol; 2013 Aug; 87(2):101-11. PubMed ID: 23838481
[TBL] [Abstract][Full Text] [Related]
36. mTOR inhibitors in the treatment of breast cancer.
Vinayak S; Carlson RW
Oncology (Williston Park); 2013 Jan; 27(1):38-44, 46, 48 passim. PubMed ID: 23461041
[TBL] [Abstract][Full Text] [Related]
37. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
38. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
Barnett CM
Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
[TBL] [Abstract][Full Text] [Related]
39. Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Abraham J; Coleman R; Elias A; Holmes FA; Kalinsky K; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Vogel C;
Breast Cancer Res Treat; 2018 Aug; 171(1):11-20. PubMed ID: 29725889
[TBL] [Abstract][Full Text] [Related]
40. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
Rugo HS; Rumble RB; Macrae E; Barton DL; Connolly HK; Dickler MN; Fallowfield L; Fowble B; Ingle JN; Jahanzeb M; Johnston SR; Korde LA; Khatcheressian JL; Mehta RS; Muss HB; Burstein HJ
J Clin Oncol; 2016 Sep; 34(25):3069-103. PubMed ID: 27217461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]